Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
Antiviral Res. 2023 Jan;209:105475. doi: 10.1016/j.antiviral.2022.105475. Epub 2022 Nov 21.
Antiviral Res. 2023.
PMID: 36423831
Free PMC article.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group.
Livingstone E, et al.
Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10.
Lancet. 2022.
PMID: 36099927
Clinical Trial.
Item in Clipboard
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Kumar S, Çalışkan DM, Janowski J, Faist A, Conrad BCG, Lange J, Ludwig S, Brunotte L.
Kumar S, et al. Among authors: conrad bcg.
Front Immunol. 2021 Oct 1;12:752227. doi: 10.3389/fimmu.2021.752227. eCollection 2021.
Front Immunol. 2021.
PMID: 34659259
Free PMC article.
Review.
Item in Clipboard
Cite
Cite